BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Glytec LLC Adds Pediatric Insulin Dosing to its IV and SubQ FDA Clearances


5/22/2012 8:42:09 AM

GREENVILLE, S.C., May 22, 2012 /PRNewswire/ -- Glytec, LLC, headquartered in Greenville, SC, announced today that its Glucommander 2.0 Enterprise software has been cleared by the FDA for pediatric use, ages 2 - 17. Glytec's Glucommander was the first insulin dosing software to be cleared for adult (ages 18+) intravenous use; it isthe only company to achieve specific clearance for subcutaneous use, and now it is the only company cleared to offer this technology to hospitals caring for children.

Hypoglycemia, hyperglycemia, and, in particular, increased glucose variability are prevalent with pediatric intensive care patients and those children suffering with diabetes in general, all of which are issues associated with increased length of stay and mortality rates. Children pose unique treatment challenges related to medications, dietary control, meal planning and physical activity, all of which necessitate effective glycemic control.

Commenting on the announcement, Trefor Thomas, CEO & President of Glytec, said, "We're very pleased that the FDA has cleared our system for use with all children as young as two, and we expect to see substantial improvement in their outcomes, similar to what adult patients have been experiencing with our system for years."

Glytec's clinician-developed, algorithm-based insulin-dosing software is a network based application designed to consider each patient's insulin sensitivity to safely stabilize excursions while achieving and maintaining glucose levels within a clinician defined target range, allowing patients to achieve safe normoglycemia. This can translate to reductions in length of stay, infection rates, readmission rates, comorbidity, and even mortality.

Thomas added, "This latest advance again demonstrates Glytec to be the industry leader in glycemic management. Our organization has worked hard to earn the FDA clearance for an application designed around the unique needs of children, and we are excited to be the first to get clearance for pediatric dosing. We will continue to work on other ways to extend the safety and efficacy of insulin as a way to control elevated blood glucose levels without causing hypoglycemia."

About Glytec, LLC
Founded in 2006 and headquartered in Greenville, South Carolina, Glytec (http://www.GlytecSystems.com) is leading the way with next generation glycemic control management systems. Glytec offers the only glycemic management system cleared for both adults and children. For further information, contact: William J. Nicholson, Marketing Director, Glytec, LLC (864) 263 4178 bnicholson@glytecsystems.com

Visit Glytec at NTI/AACN in Orlando, May 22 to 24 Booth #2437

SOURCE Glytec, LLC


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->